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Abstract
Background: Undifferentiated nasopharyngeal carcinoma (NPC) is strongly related to Epstein-Barr virus (EBV)
infection, allowing aberrant antibodies against EBV and viral DNA load as screening tools in high risk populations.
Methylation analysis in the promoter of tumor suppressor genes (TSGs) may serve as a complementary marker for
identifying early cases. This study determined methylation status of multiple TSGs and evaluated whether it may
improve early detection.
Methods: Nasopharyngeal brushings were taken from 53 NPC patients, 22 high risk subjects and 25 healthy EBV
carriers. Corresponding NPC paraffin tissue was included. DNA was bisulfite-modified preceding analysis by
methylation-specific PCR (MSP). Ten TSGs were studied.
Results: NPC paraffin and brushing DNA revealed an 81.8% concordance so that MSP analysis was done using
either one of both specimens. NPC samples showed methylation for individual TSGs (DAPK1 79.2%, CDH13 77.4%,
DLC1 76.9%, RASSF1A 75.5%, CADM1 69.8%, p16 66.0%, WIF1 61.2%, CHFR 58.5%, RIZ1 56.6% and RASSF2A 29.2%).
High risk individuals, having elevated EBV IgA and viral load, showed high frequency of methylation of CDH13,
DAPK1, DLC1 and CADM1, but low frequency of methylation of p16 and WIF1 and undetectable methylation of
RASSF1A, CHFR, RIZ1 and RASSF2A. Healthy subjects showed similar patterns as high risk individuals. A combination
of RASSF1A and p16 gave good discrimination between NPC and non-NPC, but best results were combined
analysis of five methylation markers (RASSF1A, p16, WIF1, CHFR and RIZ1) with detection rate of 98%.
Conclusion: Multiple marker MSP is proposed as a complementary test for NPC risk assessment in combination
with EBV-based markers.
Background
Nasopharyngeal carcinoma (NPC) is highly prevalent in
Southern China and South-East Asia. The incidence of
NPC in Indonesia is 6.2 cases/100,000 population per
year representing the fourth most common cancer [1].
Based on size of the Indonesian population it is esti-
mated that 13,000 new cases of NPC occur annualy.
Early detection is needed to improve patient survival
since the majority of cases are currently diagnosed at
late stage.
Given the close link between NPC and Epstein-Barr
virus (EBV) infection, detection of characteristic antibo-
dies against EBV and elevated viral load has been pro-
posed as useful screening tool [2-4]. Recently, we started
a screening protocol in the Yogyakarta region recruiting
high risk patients with chronic problems in the head
and neck area and testing them using EBV-based assays.
Although this study is still ongoing, current observations
indicate that neither method provides an adequate
stand-alone marker for detecting NPC as a primary
screening test due to their relative low positive predic-
tive value (PPV) (Hutajulu et al., unpublished data) con-
firming other reports [5,6]. The low PPV might be due
to the large number of subjects presenting with elevated
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cal mass. Indeed, antibody levels against EBV were
shown to be elevated for as long as ten years before
tumor presentation [4]. As a consequence, recruitment
of subjects by EBV-based markers alone would require
long term monitoring. CT-scan examination and naso-
pharyngeal biopsy are needed for clinical confirmation
of tumor presence. This would imply that a huge num-
ber of people would need detailed examination resulting
in unacceptably high costs. It is therefore essential to
define additional NPC progression markers for better
selection of high risk patients.
Exploration of altered cellular genes involved in NPC
development may provide a complementary test for risk
assessment in EBV infected individuals. Promoter DNA
methylation is widely considered to be an important epi-
genetic mechanism in carcinogenesis. In NPC, gene
silencing by promoter methylation has been shown for
multiple tumor suppressor genes (TSGs). Each TSG
potentially contributes to the multistep oncogenesis
including alterations of apoptosis, cell cycle and mitotic
checkpoint regulation, intracellular adhesion, cytoskele-
ton organization, and Wnt-signalling pathway [7-9].
Therefore, in the present study we determined the fre-
quency of promoter DNA methylation of multiple genes
in Indonesian NPC cases. These TSGs were proven to
be frequently methylated in NPC from other ethnic
groups [10-16]. To analyse their potential value for
detection of early-stage NPC, we compared the methyla-
tion pattern of NPC patients, healthy EBV carriers and a
high risk population. The latter group consisted of
patients with chronic head and neck complaints showing
elevated EBV markers. Furthermore, we analysed an
additional TSG, the myelin and lymphocyte-associated
protein (MAL), which has been proven methylated in
head and neck cancer [17] but has not been tested in
NPC. More importantly, MAL gene is frequently methy-
lated in cervical cancer indicating its role in virus-
related epithelial malignancy [18].
Results
EBV IgA ELISA seroreactivity
The antibody reactivity against EBV antigens was deter-
mined for all NPC, high risk and normal subjects. Ele-
vated responses were seen in 49 NPC cases (92.5%) and
3 normal subjects (12%). A high risk group was defined
(n = 22) by selecting patients who visited the ear, nose
a n dt h r o a t( E N T )d e p a r t m e n ta n ds h o w e dc h r o n i c
symptoms in the head and neck region (n = 212). All
selected subjects from this population had elevated EBV
IgA ELISA seroreactivity and detectable viral load in
their nasopharyngeal brushings. The ELISA results of
the three groups are displayed in Figure 1. The seroreac-
tivity of NPC patients and high risk individuals was
higher than that of healthy subjects and NPC cases
showed higher responses compared to the high risk
individuals (Mann-Whitney U test, all p < 0.001).
EBV DNA quantity in nasopharyngeal brushings
Quantitative analysis of EBV DNA was determined in
brushing samples from 50 NPC patients, 22 high risk
individuals and 25 healthy subjects. The viral load was
detectable in 49 NPC (98%) and all high risk isolates. In
healthy subjects viral load was detectable in 4 cases
(16%) and below the cut-off value (CoV) in 21 subjects
(84%). There was a significant difference between the
median log of EBV DNA quantity in NPC, high risk and
normal population (p < 0.001) (Figure 2). The Post Hoc
analysis using Tukey showed significant differences
between NPC and high risk individuals as well as
between NPC and normal EBV carriers (all p < 0.001).
Nasopharyngeal carcinoma patient isolates showed
frequent promoter methylation of 10 tumor suppressor
genes
For identification of methylation markers as comple-
mentary test for early detection of NPC, the frequency
of promoter methylation of 10 TSGs was determined in
NPC isolates. Identical methylation status in paraffin
biopsy and the corresponding brushing samples was
observed in 18 of 22 NPC cases, revealing an 81.8%
overall agreement. Therefore methylation status in the
NPC group was determined using either one of the two
sample types. When determined in all isolates of NPC
cases (n = 53) the frequency of promoter methylation of
all individual genes ranged from 29.2-79.2% (table 1).
p< 0.001
p< 0.001
CoV
Figure 1 Box plot of seroreactivity of IgA/[EBNA-1+VCA-p18]
ELISA by group (normal, high risk and NPC) with cut-off value of
0.354. The seroreactivity in NPC and high risk group was significantly
higher than that in normal subjects (Mann-Whitney U test all p <
0.001). NPC = nasopharyngeal carcinoma, CoV = cut-off value.
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F i f t y - t w oo f5 3( 9 8 . 1 % )N P C cases exhibited aberrant
promoter methylation in at least one of the genes stu-
died. Three (5.6%) cases showed promoter methylation
in all these genes. In one case (1.9%) none of the genes
was found to be methylated.
For analysis of the possibility of TSGs contributing to
early stage NPC the frequency of promoter methylation in
high risk and normal individuals was determined (table 1).
In the high risk population methylation was detected for
some TSGs including CDH13 (72.7%), DAPK1 (40.9%),
CADM1 (36.4%) and DLC1 (40.9%). The frequency of
methylation of p16 and WIF1 gene was low (27.2% and
18.2% respectively), whereas methylation of CHFR, RIZ1,
RASSF1A and RASSF2A gene was undetectable. In the
normal population a high frequency of methylation was
demonstrated for DAPK1 (48.0%), CDH13 (64.0%) and
DLC1 (64.0%), whereas methylation of CADM1 (72%) was
even higher than in NPC cases and high risk subjects. In
healthy EBV carriers promoter methylation was very low
for RASSF1A (4%) and undetectable for CHFR, RIZ1,
WIF1, p16 and RASSF2A. The high methylation frequency
in healthy individuals led us to evaluate methylation pat-
terns in 11 peripheral blood mononuclear cells (PBMC)
from Dutch healthy donors and 5 spontaneous lympho-
blastoid cell lines (LCL) from Indonesian healthy donors.
In these specimens the methylation frequency of the parti-
cular genes was detectable but was not as high as that of
nasopharyngeal brushing from healthy donors (DAPK1
18.8%, DLC1 18.8%, CDH13 31.3% and CADM1 43.8%,
respectively). In contrast, RASSF1A, RIZ1, CHFR, WIF1,
p16 and RASSF2A showed no detectable methylation
(data not shown).
Confirmation of methylation status using Q-MSP
To determine whether the high frequency of CADM1
promoter methylation in the normal population was
related to the level of methylation quantitative amplifi-
cation was performed. Fifteen paraffin tissues and 18
brushings from NPC patients, 15 brushings from high
risk and 11 brushings from normal individuals were
selected for Q-MSP using Taqman. As shown in Figure
4A methylation levels of CADM1 were comparable
between brushings of healthy controls, high risk subjects
and NPC cases (p = 0.654 for healthy versus NPC and p
= 0.641 for NPC versus high risk), confirming the MSP
result. NPC paraffin yielded higher methylation levels
compared to NPC brushing but the difference was not
significant (p = 0.069).
MAL promoter methylation showed good discrimination
between NPC and normal subjects
In parallel to CADM1 we analysed MAL promoter methy-
lation which was shown to be relevant in the viral onco-
genesis of cervical cancer (Figure 4B). Better
CoV
p < 0.001 
p < 0.001
Figure 2 Boxplot of (log) EBV DNA load in nasopharyngeal
brushings by group (normal, high risk and NPC). The cut-off
value was set at (log) 2,300 copies/brushing (3.362). There were
highly significant variations between median in the three groups
(one-way ANOVA, p < 0.001). Using Tukey analysis, the differrences
between median in all groups are all significant. NPC =
nasopharyngeal carcinoma, CoV = cut-off value.
Table 1 The frequency of gene promoter methylation of 10 tumor suppressor genes in NPC, high risk and normal
subjects.
Gene NPC group (paraffin and/or brushing) High Risk Group (brushing) EBV-normal carriers (brushing)
CHFR 31/53 (58.5%) 0/22 (0.0%) 0/25 (0.0%)
RIZ1 30/53 (56.6%) 0/22 (0.0%) 0/25 (0.0%)
WIF1 30/49 (61.2%) 4/22 (18.2%) 0/25 (0.0%)
p16 35/53 (66.0%) 6/22 (27.2%) 0/25 (0.0%)
RASSF2A 14/48 (29.2%) 0/22 (0.0%) 0/25 (0.0%)
RASSF1A 40/53 (75.5%) 0/22 (0.0%) 1/25 (4.0%)
DAPK1 42/53 (79.2%) 9/22 (40.9%) 12/25 (48.0%)
DLC1 40/52 (76.9%) 9/22 (40.9%) 16/25 (64.0%)
CDH13 41/53 (77.4%) 16/22 (72.7) 16/25 (64.0%)
CADM1 37/53 (69.8%) 8/22 (36.4%) 18/25 (72.0%)
In NPC group methylation status was determined either from paraffin or brushing DNA.
Frequency is presented in order of percentage in EBV-normal group from the smallest to the largest
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NPC brushing compared to brushing from healthy EBV
carriers (p = 0.070). The level of MAL methylation in
NPC paraffin and NPC brushing was similar (p = 0.315)
but in NPC paraffin it was significantly higher compared
to brushing samples from healthy persons (p = 0.002).
This indicates that MAL methylation status may be a pro-
mising additional marker for NPC detection.
A panel of 5 methylated TSGs showed best discrimination
between NPC and non-cancer individuals
In Indonesian NPC cases all 10 TSGs tested with MSP
showed high frequency of promoter methylation. How-
ever when comparing the three study groups, not all
TSGs allowed discrimination of NPC cases from non-
NPC individuals. Thus, defined genes were selected as
NPC markers with high methylation frequency including
C H F R ,R I Z 1 ,W I F 1 ,p 1 6a n dR A S S F 1 A .N P Ci s o l a t e s
showed methylation detection of 58.5-75.5% for these
genes compared to almost undetectable frequency in nor-
mal EBV carriers and partly methylated in the high risk
group (table 1). By using this panel of 5 markers the NPC
detection rate was improved compared to the individual
markers. The sensitivity and specificity of using at least
one of the markers (analysed in 50 NPC cases versus 25
normal subjects) are 98% and 96%, respectively. By using
2 markers with the highest frequency (RASSF1A and p16
gene), the sensitivity and specificity of at least one of
both are 91% and 96%, respectively.
Correlation of methylation status with other parameters
The frequency of methylation was tested in relation to
EBV parameters and age. There was a significant corre-
lation between the rate of methylation with EBV DNA
load (r = 0.322, p = 0.023) (Figure 5B), but not with
EBV IgA ELISA seroreactivity (r = -1.88 p = 0.117) (Fig-
ure 5A) and age (r = 0.270, p = 0.05) (Figure 5C). When
considering one outlier, methylation has a significant
correlation with age (r = 0.369, p = 0.007). The outlier
was a young patient from a rare multiplex NPC family.
Discussion
Methylation of promoter DNA is considered an impor-
tant epigenetic event in NPC carcinogenesis [7-9] and
Figure 3 Representative results of methylation specific PCR in the three groups. NPC isolates showed more frequent methylated genes
compared to high risk and normal isolates. L = marker, UMD = unmodied DNA, C- = negative control, C+ = positive control, NP =
nasopharyngeal carcinoma, HR = high risk, N = normal, U = unmethylated alele, M = methylated alele.
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type of tumors [18,19]. Since the profile of TSG promo-
ter methylation may vary according to tumor type [20],
this study defined epigenetic variability in NPC. Aber-
rant methylation of five TSGs was identified as indepen-
dent marker for early detection of NPC with added
value to EBV IgA serology and DNA load. For a devel-
oping country like Indonesia such a test should be eco-
nomical with simple but well standardized technology
suited for screening in a large population. Therefore
qualitative MSP is proposed, being less labor-intensive
and inexpensive compared to other assays such as Q-
MSP or bisulfite sequencing.
We selected a set of markers that have been evaluated
in various NPC populations. Since methylation changes
have been reported to occur early in carcinogenesis [7],
epigenetic markers are potentially relevant as early indi-
cators of subclinical presence of NPC. Our present
study demonstrated that the promoter methylation fre-
quency of individual TSGs is variable in NPC, confirm-
ing previous publications [10-16]. The methylation
frequency of single genes varied from 29.2% (RASSF2A
gene) to 79.2% (DAPK1 gene). This frequency is com-
parable to the one presented in other studies except for
WIF1 [12] and RASSF2A [14] where the frequency in
the Indonesian samples was much lower (61.2% and
29.2%, respectively).
For particular genes (DAPK1, CADM1, CDH13 and
DLC1), the methylation frequency is not only high in
NPC cases, but also in the high risk group and normal
EBV carriers, thus limiting their diagnostic value. The
high frequency of methylation has not been reported
before in other healthy control populations, mostly
showing a frequency below 10% [15,16,21,22]. However,
the occurrence of methylation in normal tissue was con-
firmed in PBMCs and LCLs obtained from healthy indi-
viduals. In CADM1, the high frequency of methylation
detected by MSP was explained by frequent but low
level methylation in both normal and NPC brushing
using Q-MSP. This suggested that CADM1 is not a
good marker for the early detection of NPC. Similarly
DAPK1, CDH13 and DLC1 could be considered as non-
specific markers.
A panel of methylation markers consisting of CHFR,
RIZ1, p16, WIF1 and RASSF1A is proposed as a com-
plementary test for early NPC detection. These five
TSGs showed high methylation in NPC cases and not
more than 4% in the regional healthy EBV positive con-
trols providing good differentiation between cancer
cases and normal controls. Detection of aberrant
Figure 4 Scatter diagram of relative quantity of methylation of (A) CADM1 and (B) MAL gene.T h eYa x i si se x p r e s s e di nl o gs c a l e .
CADM1 (A) showed an insignificant variations between normal brushing and NPC brushing and between NPC brushing and NPC paraffin (one-
way ANOVA using Tukey analysis p = 0.654 and 0.069 respectively). Thus Q-MSP confirmed the result of MSP. MAL (B) showed insignificant
variations between normal brushing and NPC brushing (p = 0.070). Methylation level in NPC paraffin was comparable to NPC brushing (p =
0.069) but was significantly higher compared to normal brushing (p = 0.002) indicating that MAL methylation can be a promising marker for
NPC detection. HR = high risk, NPC = nasopharyngeal carcinoma.
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of 98% in NPC group compared to individual markers.
In particular, detection of aberrant methylation of p16
and RASSF1A may provide more simple testing with
specificity and sensitivity above 90%.
Pilot testing of MAL methylation using Q-MSP
revealed this gene as an additional discriminator
between NPC and normal controls. As explored pre-
viously in cervical [18] the MAL gene may play a speci-
fic role in viral-epithelial malignancies. Since the MAL
gene has not been analysed in NPC before, this report is
the first to describe it as a promising marker for further
investigation.
Comparing paraffin tissue and brushing samples of
NPC cases revealed a good detection of methylation for
both sample types, supporting the results of Sun et al.
[16]. Nasopharyngeal brushing is proposed for sampling
in population screening studies considering it is conve-
nient and simple. When determined only on brushing
samples, methylation of any marker of the selected
genes was detected in 39 out of 41 NPC cases (95.1%).
This is comparable to the assessment using either paraf-
fin or brushing which detected methylation in 98% of
NPC. Moreover, this minimal invasive procedure yielded
high PPV (>90%) compared to biopsy and reproducible
high yields of cellular DNA (10
6-10
7 genome copies/
brush). Nasopharyngeal brushing is also an excellent
sampling method for monitoring EBV DNA load and
EBV mRNA expression, each having good diagnostic
value [23].
Our present study did not demonstrate a significant
difference between methylation frequency in early and
late stage NPC cases (data not shown). To evaluate the
capacity of epigenetic markers to detect preclinical
Figure 5 Scatter diagram of (A) ELISA seroreactivity on 53 NPC sera, (B) log EBV DNA load on 50 NPC brushings and (C) age of 53
NPC cases versus number of methylated tumor suppressor genes. The correlation with methylation rate is significant but weak for EBV
DNA load (Pearson correlation r = 0.322, p = 0.023) and insignificant for ELISA seroreactivity (r = -1.88 p = 0.117) and age (r = 0.270, p = 0.05).
The latter becomes significant when excluding a young patient from a multiplex family (symbolized with star) (p = 0.007).
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the local high risk population. Compared to the baseline
observation, this cohort revealed an increased frequency
of methylation of p16 and RIZ1. The presence of p16
methylation supports previous reports showing p16 gene
silencing in precancerous lesions of NPC. However our
data do not confirm RASSF1A methylation in premalig-
nant tissues [7]. This indicates that epigenetic changes
leading to malignancy in the Indonesian population may
differ from other populations. Which gene silencing
event initiates NPC development and which contributes
to further progression of the multistep carcinogenic pro-
cess remains to be investigated.
The correlation found between methylation status and
viral DNA load in Indonesian NPC cases indicates a link
between epigenetic events and EBV infection. The
appropriate level of DNA load in our NPC samples may
directly reflect a (pre)malignant process. This is in
agreement with a previous data on matched NPC tumor
and adjacent tissues. The nearer to the NPC tissue, the
higher the levels of gene promoter methylation and EBV
DNA load found [11]. More recent studies implied the
role of EBV genes in epigenetic silencing either through
activation of DNA methyltransferases [24] or interaction
with transcriptional repression [25].
Factors known to contribute to methylation alterations
include age, diet and lifestyle [26,27]. Regarding the fac-
tor of age, our result on Indonesian NPC showed a ten-
dency for methylation frequency to increase with age.
This reflects accumulative epigenetic events under the
influence of environmental exposures that may increase
with time. Considering the factor of diet, our observation
in the local population demonstrates that diet might also
predispose one towards cancer development. Formalde-
hyde, boric acid, Rhodamine B, and yellow Metanyl are
among many reported chemicals found in the food of
local markets in Indonesia [28]. Persistent exposure to
environmental toxins is indicated as an initial step of epi-
genetic alteration preceding cancer development [29-31].
This might explain the high frequency of methylation of
certain genes observed in the Indonesian healthy popula-
tion. The potential relationship between carcinogenic
exposure and promoter methylation status is subject to
further study. Analysis of the methylation status of
selected genes is proposed as additive test for NPC risk
assessment using EBV-based assays in primary screening.
The epigenetic markers described here provide comple-
mentary information in a subgroup of high risk indivi-
duals with aberrant EBV IgA seroreactivity and elevated
viral load. In a case-finding approach, screening subjects
presenting with symptoms suspicious of NPC, this
approach may identify those subjects at highest risk of
NPC development.
Conclusion
Indonesian NPC cases showed more frequent methy-
lated TSGs compared to high risk and normal indivi-
duals implicating epigenetic changes in NPC
development and suggesting their utility for NPC identi-
fication. DNA promoter methylation of defined sets of
genes may serve as a complementary test for early NPC
detection in combination with EBV-based markers. Such
a test should include p16 and RASSF1A possibly com-
bined with CHFR, RIZ1, WIF1 and MAL.
Materials and methods
Patients and biological samples
Paraffin-embedded tissue from 34 NPC patients before
treatment were selected from the pathology archives of
Dr. Sardjito Teaching Hospital Yogyakarta [23]. Corre-
sponding nasopharyngeal brushings were collected from
22 of these patients. Single nasopharyngeal brushing
samples from 19 NPC cases were obtained yielding 53
overal NPC cases. NPC cases were histologically con-
firmed as undifferentiated NPC (WHO type 3). Presence
of EBV was confirmed by EBV-encoded small RNA
(EBER) detection in all cases [23]. Staging was done
according to the AJCC 2004 criteria with 44 patients
(80%) at late stage NPC (3 or 4) and 9 patients at early
stage (1 or 2). Twenty-two individuals with chronic
symptoms suggestive for early NPC [4] and having ele-
vated EBV markers were selected as the high risk popu-
lation. Twenty-five asymptomatic EBV carriers were
recruited consisting of 9 Dutch and 16 Indonesian sub-
jects. All participants were recruited with informed con-
sent to give blood and nasopharyngeal brushings.
DNA extraction and bisulfite modification
Genomic DNA from nasopharyngeal brushings was iso-
lated using silica-based extraction [32] (Basic kit, Bio-
Merieux, Boxtel, The Netherlands). DNA isolation from
paraffin-embedded tissue was performed using the Che-
lex method [33]. Of each DNA sample 500 ng was used
for bisulfite treatment using a commercially available
DNA modification kit (EZ DNA Methylation Kit™;
Zymo Research, Orange, CA, USA).
EBV markers
EBV specific IgA reactivity was assessed in all sera by a
synthetic peptide based enzyme-linked immunosorbent
assay (ELISA) for immunodominant epitopes derived
from Epstein-Barr virus nuclear antigen 1 (EBNA-1) and
viral capsid antigen (VCA)-p18 (further referred to as
EBV IgA ELISA). The ELISA CoV was 0.354 as pre-
viously defined [34]. EBV DNA load in nasopharyngeal
(NP) brushings was determined by quantitative LightCy-
cler (LC) real-time PCR targeting a 213 bp conserved
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copies/brushing presenting the mean+3*SD of a cohort
of controls [23].
Methylation-specific PCR (MSP) and quantitative MSP (Q-
MSP)
MSP targeted regions within promoters of 10 TSGs
including CHFR [36], RIZ1 [37], WIF1 [12], p16 [38],
RASSF1A [39], RASSF2A [40], DAPK1 [41], DLC1 [15],
CDH13 [42] and CADM1 [43]. The sequences of PCR
primers specific for unmethylated and methylated alleles
of all targets were identical as previously published. Fas-
tStart Taq PCR and Amplitaq Gold (Roche Diagnostics
Netherlands BV) were used for ampification. The EBV
positive Burkitt’s lymphoma cell line (Namalwa), EBV
negative nasopharyngeal carcinoma cell line (HONE-1),
cervical cancer cell lines (CaSki, SiHa), human lung ade-
nocarcinoma cell line (Calu-6), human colon carcinoma
cell line (RKO) and primary human foreskin keratino-
cytes (EK) were included as positive and negative PCR
controls for either unmethylated or methylated amplifi-
cation. For these cell lines methylation status of indivi-
dual TSGs was known [10-12,15,16,44]. As negative
controls, H2O, bisulfite modified DNA of primary kera-
tinocytes and unmodified methylated DNA from cell
lines or brushing samples were included.
Quantitative-MSP (Q-MSP) was conducted using pri-
mer sets targeting the CADM1 and the MAL gene pro-
moter. Amplicons were detected and quantified using
Taqman probes. Primer/probe sequence for CADM1 is
(forward) ATTTTATTACTTCTTCGTTCGGGT, (probe)
ACCTACCTCAAACTAACGACGTTAACTACCTCCGA
and (reverse) CTCGACAACACTACACTCGCC [45].
The Q-MSP amplicon largely overlaps the conventional
MSP amplicon (CADM1 region M9) [43]. Primer/
probe sequences for the MAL promoter were described
previously [18]. Q-MSP was set up using QuantiTect
Probe PCR Kit master mix (Qiagen, Westburg, Leus-
den, The Netherlands). For each Q-MSP a standard
curve consisting of serial dilutions of bisulfite-treated
DNA of the SiHa cervical cell line was used. The
housekeeping gene b-actin was applied as an internal
reference. To determine the relative quantity of methy-
lation, ratios between methylated CADM1 or MAL
DNA versus b-actin DNA was performed (average
quantity of methylated CADM1/MAL DNA/average
DNA quantity for b-actin × 1000).
Statistical analysis
Differences of methylation status between the three
groups versus other diagnostic parameters were analysed
using one-way analysis of variance (ANOVA) (EBV
DNA load) or Mann-Whitney U test (ELISA seroreactiv-
ity). Differences of methylation status in Q-MSP were
analysed using one-way ANOVA. The correlation
between methylation status and ELISA seroreactivity,
EBV DNA load and age was assessed using the Pearson
correlation test. p < 0.05 was considered significant. All
statistical calculations were performed using SPSS ver-
sion 15.0.
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